Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 4,836 shares, an increase of 62.8% from the October 15th total of 2,971 shares. Based on an average trading volume of 18,086 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the shares of the company are short sold.
Cardio Diagnostics Price Performance
Shares of CDIO traded up $0.10 during midday trading on Monday, hitting $1.97. The stock had a trading volume of 505 shares, compared to its average volume of 1,171,424. The firm has a market cap of $5.82 million, a PE ratio of -0.78 and a beta of 2.32. The stock’s 50 day moving average is $1.85 and its 200 day moving average is $2.06. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91.
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.59) earnings per share for the quarter. Cardio Diagnostics had a negative return on equity of 89.41% and a negative net margin of 40,543.75%.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Cardio Diagnostics stock. Renaissance Technologies LLC acquired a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned 0.52% of Cardio Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
View Our Latest Research Report on CDIO
Cardio Diagnostics Company Profile
Cardio Diagnostics Holdings, Inc. develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease. The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.
Featured Articles
- Five stocks we like better than Cardio Diagnostics
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
